Y-Intercept (HK)’s Summit Therapeutics SMMT Stock Holding History

Y-Intercept (HK)’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$863K	Buy	+51,025	New	+$763K	0.02%	1078
2026 Q2	–	Sell	-119,655	Closed	-$2.27M	–	2132
2026 Q1	$2.27M	Buy	+119,655	New	+$1.94M	0.04%	657
2023 Q2	–	Sell	-39,337	Closed	-$68.8K	–	1691
2023 Q1	$68.8K	Buy	+39,337	New	+$107K	0.01%	1090
2022 Q3	–	Sell	-10,355	Closed	-$10K	–	1247
2022 Q2	$10K	Buy	+10,355	New	+$14.5K	﹤0.01%	814

Other funds holding SMMT

Griffin Asset Management New York $934M AUM 18.69% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Wealth Management Partners Tucson, Arizona $426M AUM 43.17% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return

Blankinship & Foster Solana Beach, California $490M AUM 14.37% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Y-Intercept (HK)'s SMMT Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 51,025 shares worth $863K. The stake represents 0.02% of the portfolio and ranks #1078 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in SMMT as recently as Q1 2026.

Y-Intercept (HK) first reported a position in SMMT in Q2 2022 and has held it in 4 quarters since. The position peaked at $2.27M in Q1 2026. 32 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

Y-Intercept (HK) held 51,025 shares of Summit Therapeutics worth $863K as of Q3 2026.
Summit Therapeutics was a new Y-Intercept (HK) position in Q3 2026.
Summit Therapeutics made up 0.02% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1078 holding.
Y-Intercept (HK) first reported a position in Summit Therapeutics in Q2 2022 and has held it in 4 quarters since.
Y-Intercept (HK)'s Summit Therapeutics position peaked at $2.27M in Q1 2026.
32 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.